Protein tyrosine phosphatases as novel targets in breast cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 211-226

  Nunes Xavier, Caroline E ^a   Martín Pérez, Jorge ^b   Elson, Ari ^c   Pulido, Rafael ^a,d  

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Breast cancer; Cell signaling; Drug targeting; Protein tyrosine kinase; Protein tyrosine phosphatase; Therapy resistance

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; AROMATASE INHIBITOR; BETULIC ACID; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETIDRONIC ACID; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; STIBOGLUCONATE SODIUM; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CHEMOSENSITIVITY; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW;

17Β-ESTRADIOL; ASP; ASPARTIC ACID; BC; BCCL; BREAST CANCER; BREAST CANCER CELL LINE; C-JUN N-TERMINAL KINASE; CELL SIGNALING; CENTRAL NERVOUS SYSTEM; CNS; CYS; CYSTEINE; DRUG TARGETING; DUAL SPECIFICITY PHOSPHATASE; DUSP; E2; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ER; ERK; ESTROGEN RECEPTOR; EXTRACELLULAR-SIGNAL REGULATED KINASE; HER; HGR; HORMONE GROWTH RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR; IGF1R; INSULIN GROWTH FACTOR-LIKE 1 RECEPTOR; INSULIN RECEPTOR; IR; JAK; JANUS KINASE; JMML; JNK; JUVENILE MYEOLOMONOCYTIC LEUKAEMIA; LEOPARD SYNDROME; LS; MAB; MAMMALIAN TARGET OF RAPAMYCIN; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MTOR; NON-RECEPTOR PTP; NOONAN SYNDROME; NS; PDGFR; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; PR; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PTK; PTP; PTPN/NRPTP; PTPR/RPTP; RECEPTOR-LIKE PTP; SER; SERINE; SFK; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; SINGLE-NUCLEOTIDE POLYMORPHISM; SNP; SRC-FAMILY KINASE; STAT; THERAPY RESISTANCE; THR; THREONINE; TNBC; TRIPLE NEGATIVE BREAST CANCER; TYR; TYROSINE; VASCULAR-ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84879713811     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.06.001     Document Type: Review

References (274)

1. Weigelt B., Geyer F.C., Reis-Filho J.S. Histological types of breast cancer: how special are they?. Mol. Oncol. 2010, 4:192-208.
2. Hynes N.E. Tyrosine kinase signalling in breast cancer. Breast Cancer Res. 2000, 2:154-157.
3. Hochgrafe F., Zhang L., O'Toole S.A., Browne B.C., Pinese M., Porta Cubas A., Lehrbach G.M., Croucher D.R., Rickwood D., Boulghourjian A., Shearer R., Nair R., Swarbrick A., Faratian D., Mullen P., Harrison D.J., Biankin A.V., Sutherland R.L., Raftery M.J., Daly R.J. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res. 2010, 70:9391-9401.
4. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011, 11:35-49.
5. Ostman A., Hellberg C., Bohmer F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6:307-320.
6. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7:833-846.
7. Hennipman A., van Oirschot B.A., Smits J., Rijksen G., Staal G.E. Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 1989, 49:516-521.
8. Ottenhoff-Kalff A.E., van Oirschot B.A., Hennipman A., de Weger R.A., Staal G.E., Rijksen G. Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer. Breast Cancer Res. Treat. 1995, 33:245-256.
9. Freiss G., Vignon F. Protein tyrosine phosphatases and breast cancer. Crit. Rev. Oncol. Hematol. 2004, 52:9-17.
10. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
11. den Hertog J., Groen A., van der Wijk T. Redox regulation of protein-tyrosine phosphatases. Arch. Biochem. Biophys. 2005, 434:11-15.
12. Tonks N.K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005, 121:667-670.
13. Ostman A., Frijhoff J., Sandin A., Bohmer F.D. Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem. 2011, 150:345-356.
14. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008, 27:253-261.
15. Nunes-Xavier C., Roma-Mateo C., Rios P., Tarrega C., Cejudo-Marin R., Tabernero L., Pulido R. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem. 2011, 11:109-132.
16. Bessette D.C., Qiu D., Pallen C.J. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008, 27:231-252.
17. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
18. den Hertog J., Ostman A., Bohmer F.D. Protein tyrosine phosphatases: regulatory mechanisms. FEBS J. 2008, 275:831-847.
19. Bohmer F., Szedlacsek S., Tabernero L., Ostman A., den Hertog J. Protein tyrosine phosphatase structure-function relationships in regulation and pathogenesis. FEBS J. 2013, 280:413-431.
20. Mohebiany A.N., Nikolaienko R.M., Bouyain S., Harroch S. Receptor-type tyrosine phosphatase ligands: looking for the needle in the haystack. FEBS J. 2013, 280:388-400.
21. Xu Y., Fisher G.J. Receptor type protein tyrosine phosphatases (RPTPs)-roles in signal transduction and human disease. J. Cell Commun. Signal. 2012, 6:125-138.
22. Östman A., Böhmer F.D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001, 11:258-266.
23. Tiganis T., Bennett A.M. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J. 2007, 402:1-15.
24. Prenzel N., Fischer O.M., Streit S., Hart S., Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 2001, 8:11-31.
25. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004, 319:1-11.
26. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, 2:203-210.
27. Prenzel N., Zwick E., Leserer M., Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2000, 2:184-190.
28. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22:337-358.
29. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
30. Roskoski R. Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun. 2004, 324:1155-1164.
31. Okada M. Regulation of the SRC family kinases by csk. Int. J. Biol. Sci. 2012, 8:1385-1397.
32. Egan C., Pang A., Durda D., Cheng H.C., Wang J.H., Fujita D.J. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 1999, 18:1227-1237.
33. Hynes N.E., Horsch K., Olayioye M.A., Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer 2001, 8:151-159.
34. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017-8023.
35. Castaneda C.A., Cortes-Funes H., Gomez H.L., Ciruelos E.M. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010, 29:751-759.
36. Roussidis A.E., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. 2007, 14:735-743.
37. Gastaldi S., Comoglio P.M., Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for?. Breast Cancer Res. 2010, 12:208.
38. Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta 2010, 1806:108-121.
39. Morandi A., Plaza-Menacho I., Isacke C.M. RET in breast cancer: functional and therapeutic implications. Trends Mol. Med. 2011, 17:149-157.
40. Yang Y., Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2012, 17:251-261.
41. Wang Z., Shen D., Parsons D.W., Bardelli A., Sager J., Szabo S., Ptak J., Silliman N., Peters B.A., van der Heijden M.S., Parmigiani G., Yan H., Wang T.L., Riggins G., Powell S.M., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166.
42. Levea C.M., McGary C.T., Symons J.R., Mooney R.A. PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer. Breast Cancer Res. Treat. 2000, 64:221-228.
43. Yang T., Zhang J.S., Massa S.M., Han X., Longo F.M. Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue. Mol. Carcinog. 1999, 25:139-149.
44. Zhai Y.F., Beittenmiller H., Wang B., Gould M.N., Oakley C., Esselman W.J., Welsch C.W. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res. 1993, 53:2272-2278.
45. Zhai Y., Wirth J., Kang S., Welsch C.W., Esselman W.J. LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells. Mol. Carcinog. 1995, 14:103-110.
46. Muller T., Choidas A., Reichmann E., Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J. Biol. Chem. 1999, 274:10173-10183.
47. Schaapveld R.Q., Schepens J.T., Robinson G.W., Attema J., Oerlemans F.T., Fransen J.A., Streuli M., Wieringa B., Hennighausen L., Hendriks W.J. Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev. Biol. 1997, 188:134-146.
48. Ausavarat S., Tongkobpetch S., Praphanphoj V., Mahatumarat C., Rojvachiranonda N., Snabboon T., Markello T.C., Gahl W.A., Suphapeetiporn K., Shotelersuk V. PTPRF is disrupted in a patient with syndromic amastia. BMC Med. Genet. 2011, 12:46.
49. Chagnon M.J., Uetani N., Tremblay M.L. Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. Biochem. Cell Biol. 2004, 82:664-675.
50. Stryker E., Johnson K.G. LAR, liprin alpha and the regulation of active zone morphogenesis. J. Cell Sci. 2007, 120:3723-3728.
51. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., Abbott R.M., Hoog J., Dooling D.J., Koboldt D.C., Schmidt H., Kalicki J., Zhang Q., Chen L., Lin L., Wendl M.C., McMichael J.F., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Appelbaum E., Deschryver K., Davies S., Guintoli T., Lin L., Crowder R., Tao Y., Snider J.E., Smith S.M., Dukes A.F., Sanderson G.E., Pohl C.S., Delehaunty K.D., Fronick C.C., Pape K.A., Reed J.S., Robinson J.S., Hodges J.S., Schierding W., Dees N.D., Shen D., Locke D.P., Wiechert M.E., Eldred J.M., Peck J.B., Oberkfell B.J., Lolofie J.T., Du F., Hawkins A.E., O'Laughlin M.D., Bernard K.E., Cunningham M., Elliott G., Mason M.D., Thompson D.M., Ivanovich J.L., Goodfellow P.J., Perou C.M., Weinstock G.M., Aft R., Watson M., Ley T.J., Wilson R.K., Mardis E.R. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
52. Ruivenkamp C.A., van Wezel T., Zanon C., Stassen A.P., Vlcek C., Csikos T., Klous A.M., Tripodis N., Perrakis A., Boerrigter L., Groot P.C., Lindeman J., Mooi W.J., Meijjer G.A., Scholten G., Dauwerse H., Paces V., van Zandwijk N., van Ommen G.J., Demant P. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. 2002, 31:295-300.
53. Smart C.E., Askarian Amiri M.E., Wronski A., Dinger M.E., Crawford J., Ovchinnikov D.A., Vargas A.C., Reid L., Simpson P.T., Song S., Wiesner C., French J.D., Dave R.K., da Silva L., Purdon A., Andrew M., Mattick J.S., Lakhani S.R., Brown M.A., Kellie S. Expression and function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors. PLoS One 2012, 7:e40742.
54. Keane M.M., Lowrey G.A., Ettenberg S.A., Dayton M.A., Lipkowitz S. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 1996, 56:4236-4243.
55. Ostman A., Yang Q., Tonks N.K. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9680-9684.
56. Grazia Lampugnani M., Zanetti A., Corada M., Takahashi T., Balconi G., Breviario F., Orsenigo F., Cattelino A., Kemler R., Daniel T.O., Dejana E. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 2003, 161:793-804.
57. Jandt E., Denner K., Kovalenko M., Ostman A., Bohmer F.D. The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion. Oncogene 2003, 22:4175-4185.
58. Pera I.L., Iuliano R., Florio T., Susini C., Trapasso F., Santoro M., Chiariotti L., Schettini G., Viglietto G., Fusco A. The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene 2005, 24:3187-3195.
59. Lesueur F., Pharoah P.D., Laing S., Ahmed S., Jordan C., Smith P.L., Luben R., Wareham N.J., Easton D.F., Dunning A.M., Ponder B.A. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum. Mol. Genet. 2005, 14:2349-2356.
60. Mita Y., Yasuda Y., Sakai A., Yamamoto H., Toyooka S., Gunduz M., Tanabe S., Naomoto Y., Ouchida M., Shimizu K. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J. Cancer Res. Clin. Oncol. 2010, 136:249-259.
61. Paduano F., Dattilo V., Narciso D., Bilotta A., Gaudio E., Menniti M., Agosti V., Palmieri C., Perrotti N., Fusco A., Trapasso F., Iuliano R. Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J. 2013, 280:401-412.
62. Iuliano R., Le Pera I., Cristofaro C., Baudi F., Arturi F., Pallante P., Martelli M.L., Trapasso F., Chiariotti L., Fusco A. The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 2004, 23:8432-8438.
63. Trapasso F., Yendamuri S., Dumon K.R., Iuliano R., Cesari R., Feig B., Seto R., Infante L., Ishii H., Vecchione A., During M.J., Croce C.M., Fusco A. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis 2004, 25:2107-2114.
64. Trapasso F., Drusco A., Costinean S., Alder H., Aqeilan R.I., Iuliano R., Gaudio E., Raso C., Zanesi N., Croce C.M., Fusco A. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol. 2006, 25:376-382.
65. Takahashi T., Takahashi K., St John P.L., Fleming P.A., Tomemori T., Watanabe T., Abrahamson D.R., Drake C.J., Shirasawa T., Daniel T.O. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol. Cell. Biol. 2003, 23:1817-1831.
66. Takahashi T., Takahashi K., Mernaugh R.L., Tsuboi N., Liu H., Daniel T.O. A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood 2006, 108:1234-1242.
67. Ramaswamy B., Majumder S., Roy S., Ghoshal K., Kutay H., Datta J., Younes M., Shapiro C.L., Motiwala T., Jacob S.T. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol. Endocrinol. 2009, 23:176-187.
68. Yu M., Lin G., Arshadi N., Kalatskaya I., Xue B., Haider S., Nguyen F., Boutros P.C., Elson A., Muthuswamy L.B., Tonks N.K., Muthuswamy S.K. Expression profiling during mammary epithelial cell 3D morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2 mediated transformation. Mol. Cell. Biol. 2012, 32:3913-3924.
69. Motiwala T., Kutay H., Ghoshal K., Bai S., Seimiya H., Tsuruo T., Suster S., Morrison C., Jacob S.T. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13844-13849.
70. Amoui M., Suhr S.M., Baylink D.J., Lau K.H. An osteoclastic protein-tyrosine phosphatase may play a role in differentiation and activity of human monocytic U-937 cell-derived, osteoclast-like cells. Am. J. Physiol. Cell Physiol. 2004, 287:C874-C884.
71. Lau K.H., Wu L.W., Sheng M.H., Amoui M., Suhr S.M., Baylink D.J. An osteoclastic protein-tyrosine phosphatase is a potential positive regulator of the c-Src protein-tyrosine kinase activity: a mediator of osteoclast activity. J. Cell. Biochem. 2006, 97:940-955.
72. Lucci M.A., Orlandi R., Triulzi T., Tagliabue E., Balsari A., Villa-Moruzzi E. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell. Oncol. 2010, 32:361-372.
73. Wang S.E., Wu F.Y., Shin I., Qu S., Arteaga C.L. Transforming growth factor beta (TGF-beta)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-beta function. Mol. Cell. Biol. 2005, 25:4703-4715.
74. Fuchs M., Muller T., Lerch M.M., Ullrich A. Association of human protein-tyrosine phosphatase kappa with members of the armadillo family. J. Biol. Chem. 1996, 271:16712-16719.
75. Xu Y., Tan L.J., Grachtchouk V., Voorhees J.J., Fisher G.J. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J. Biol. Chem. 2005, 280:42694-42700.
76. Anders L., Mertins P., Lammich S., Murgia M., Hartmann D., Saftig P., Haass C., Ullrich A. Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity. Mol. Cell. Biol. 2006, 26:3917-3934.
77. Perez-Pinera P., Garcia-Suarez O., Menendez-Rodriguez P., Mortimer J., Chang Y., Astudillo A., Deuel T.F. The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 2007, 362:5-10.
78. Foehr E.D., Lorente G., Kuo J., Ram R., Nikolich K., Urfer R. Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 2006, 66:2271-2278.
79. Pariser H., Ezquerra L., Herradon G., Perez-Pinera P., Deuel T.F. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem. Biophys. Res. Commun. 2005, 332:664-669.
80. Diamantopoulou Z., Kitsou P., Menashi S., Courty J., Katsoris P. Loss of receptor protein tyrosine phosphatase beta/zeta (RPTPbeta/zeta) promotes prostate cancer metastasis. J. Biol. Chem. 2012, 287:40339-40349.
81. Fujikawa A., Chow J.P., Shimizu H., Fukada M., Suzuki R., Noda M. Tyrosine phosphorylation of ErbB4 is enhanced by PSD95 and repressed by protein tyrosine phosphatase receptor type Z. J. Biochem. 2007, 142:343-350.
82. Dube N., Tremblay M.L. Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim. Biophys. Acta 2005, 1754:108-117.
83. Stuible M., Doody K.M., Tremblay M.L. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev. 2008, 27:215-230.
84. Tonks N.K. PTP1B: from the sidelines to the front lines!. FEBS Lett. 2003, 546:140-148.
85. Wiener J.R., Kerns B.J., Harvey E.L., Conaway M.R., Iglehart J.D., Berchuck A., Bast R.C. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl. Cancer Inst. 1994, 86:372-378.
86. Arias-Romero L.E., Saha S., Villamar-Cruz O., Yip S.C., Ethier S.P., Zhang Z.Y., Chernoff J. Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 2009, 69:4582-4588.
87. Bentires-Alj M., Neel B.G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 2007, 67:2420-2424.
88. Julien S.G., Dube N., Read M., Penney J., Paquet M., Han Y., Kennedy B.P., Muller W.J., Tremblay M.L. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 2007, 39:338-346.
89. Balavenkatraman K.K., Aceto N., Britschgi A., Mueller U., Bence K.K., Neel B.G., Bentires-Alj M. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol. Cancer Res. 2011, 9:1377-1384.
90. Berman-Golan D., Granot-Attas S., Elson A. Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis. Cancer Metastasis Rev. 2008, 27:193-203.
91. Meyer D.S., Aceto N., Sausgruber N., Brinkhaus H., Muller U., Pallen C.J., Bentires-Alj M. Tyrosine phosphatase PTPalpha contributes to HER2-evoked breast tumor initiation and maintenance. Oncogene 2013, [in press].
92. Bjorge J.D., Pang A., Fujita D.J. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem. 2000, 275:41439-41446.
93. Cortesio C.L., Chan K.T., Perrin B.J., Burton N.O., Zhang S., Zhang Z.Y., Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J. Cell Biol. 2008, 180:957-971.
94. Brown-Shimer S., Johnson K.A., Hill D.E., Bruskin A.M. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 1992, 52:478-482.
95. Buckley D.A., Cheng A., Kiely P.A., Tremblay M.L., O'Connor R. Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. Mol. Cell. Biol. 2002, 22:1998-2010.
96. Dube N., Cheng A., Tremblay M.L. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1834-1839.
97. Haj F.G., Markova B., Klaman L.D., Bohmer F.D., Neel B.G. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J. Biol. Chem. 2003, 278:739-744.
98. Lessard L., Labbe D.P., Deblois G., Begin L.R., Hardy S., Mes-Masson A.M., Saad F., Trotman L.C., Giguere V., Tremblay M.L. PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res. 2012, 72:1529-1537.
99. Zhang S., Zhang Z.Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov. Today 2007, 12:373-381.
100. Popov D. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control. Biochem. Biophys. Res. Commun. 2011, 410:377-381.
101. Tonks N.K., Muthuswamy S.K. A brake becomes an accelerator: PTP1B-a new therapeutic target for breast cancer. Cancer Cell 2007, 11:214-216.
102. Soysal S., Obermann E.C., Gao F., Oertli D., Gillanders W.E., Viehl C.T., Muenst S. PTP1B expression is an independent positive prognostic factor in human breast cancer. Breast Cancer Res. Treat. 2012, 137:637-644.
103. Lessard L., Stuible M., Tremblay M.L. The two faces of PTP1B in cancer. Biochim. Biophys. Acta 2010, 1804:613-619.
104. Yip S.C., Saha S., Chernoff J. PTP1B: a double agent in metabolism and oncogenesis. Trends Biochem. Sci. 2010, 35:442-449.
105. van Vliet C., Bukczynska P.E., Puryer M.A., Sadek C.M., Shields B.J., Tremblay M.L., Tiganis T. Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat. Immunol. 2005, 6:253-260.
106. Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C., Galic S., Tremblay M.L., Russell S.M., Godfrey D.I., Tiganis T. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 2011, 121:4758-4774.
107. Shields B.J., Wiede F., Gurzov E.N., Wee K., Hauser C., Zhu H.J., Molloy T.J., O'Toole S.A., Daly R.J., Sutherland R.L., Mitchell C.A., McLean C.A., Tiganis T. TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol. Cell. Biol. 2013, 33:557-570.
108. Blanquart C., Karouri S.E., Issad T. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem. Biophys. Res. Commun. 2009, 387:748-753.
109. Blanquart C., Karouri S.E., Issad T. Protein tyrosine phosphatase-1B and T-cell protein tyrosine phosphatase regulate IGF-2-induced MCF-7 cell migration. Biochem. Biophys. Res. Commun. 2010, 392:83-88.
110. Mattila E., Marttila H., Sahlberg N., Kohonen P., Tahtinen S., Halonen P., Perala M., Ivaska J. Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer 2010, 10:7.
111. Chong Z.Z., Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol. 2007, 22:1251-1267.
112. Somani A.K., Bignon J.S., Mills G.B., Siminovitch K.A., Branch D.R. Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J. Biol. Chem. 1997, 272:21113-21119.
113. Chiang G.G., Sefton B.M. Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J. Biol. Chem. 2001, 276:23173-23178.
114. Walter A.O., Peng Z.Y., Cartwright C.A. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene 1999, 18:1911-1920.
115. Yang X., Dutta U., Shaw L.M. SHP2 mediates the localized activation of Fyn downstream of the alpha6beta4 integrin to promote carcinoma invasion. Mol. Cell. Biol. 2010, 30:5306-5317.
116. Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., Luo J., Thompson J.A., Schraven B.L., Philips M.R., Neel B.G. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 2004, 13:341-355.
117. Poole A.W., Jones M.L. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell. Signal. 2005, 17:1323-1332.
118. Craggs G., Kellie S. A functional nuclear localization sequence in the C-terminal domain of SHP-1. J. Biol. Chem. 2001, 276:23719-23725.
119. Sathish J., Matthews R. SHP-1 twelve years on: structure, ligands, substrates and biological roles, topics in current genetics. Protein Phosphatases 2004, 301-331.
120. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
121. Chan G., Kalaitzidis D., Neel B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008, 27:179-192.
122. Chan R.J., Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007, 109:862-867.
123. Yip S.S., Crew A.J., Gee J.M., Hui R., Blamey R.W., Robertson J.F., Nicholson R.I., Sutherland R.L., Daly R.J. Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer 2000, 88:363-368.
124. Insabato L., Amelio I., Quarto M., Zannetti A., Tolino F., de Mauro G., Cerchia L., Riccio P., Baumhoer D., Condorelli G., Terracciano L., de Franciscis V. Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. Oncology 2009, 77:378-384.
125. Montano X. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation. Oncogene 2009, 28:3787-3800.
126. Essmann F., Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br. J. Pharmacol. 2012, 165:328-344.
127. Amin S., Kumar A., Nilchi L., Wright K., Kozlowski M. Breast cancer cells proliferation is regulated by tyrosine phosphatase SHP1 through c-jun N-terminal kinase and cooperative induction of RFX-1 and AP-4 transcription factors. Mol. Cancer Res. 2011, 9:1112-1125.
128. Wu C., Guan Q., Wang Y., Zhao Z.J., Zhou G.W. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell. Biochem. 2003, 90:1026-1037.
129. Tartaglia M., Niemeyer C.M., Shannon K.M., Loh M.L. SHP-2 and myeloid malignancies. Curr. Opin. Hematol. 2004, 11:44-50.
130. Tartaglia M., Gelb B.D. Germ-line and somatic PTPN11 mutations in human disease. Eur. J. Med. Genet. 2005, 48:81-96.
131. Jongmans M.C., van der Burgt I., Hoogerbrugge P.M., Noordam K., Yntema H.G., Nillesen W.M., Kuiper R.P., Ligtenberg M.J., van Kessel A.G., van Krieken J.H., Kiemeney L.A., Hoogerbrugge N. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur. J. Hum. Genet. 2011, 19:870-874.
132. Zhou X., Coad J., Ducatman B., Agazie Y.M. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 2008, 53:389-402.
133. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., Neel B.G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64:8816-8820.
134. Matozaki T., Murata Y., Saito Y., Okazawa H., Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009, 100:1786-1793.
135. Zhou X., Agazie Y.M. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J. Biol. Chem. 2009, 284:12226-12234.
136. Agazie Y.M., Hayman M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell. Biol. 2003, 23:7875-7886.
137. Wang F.M., Liu H.Q., Liu S.R., Tang S.P., Yang L., Feng G.S. SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res. Treat. 2005, 89:5-14.
138. Aceto N., Sausgruber N., Brinkhaus H., Gaidatzis D., Martiny-Baron G., Mazzarol G., Confalonieri S., Quarto M., Hu G., Balwierz P.J., Pachkov M., Elledge S.J., van Nimwegen E., Stadler M.B., Bentires-Alj M. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med. 2012, 18:529-537.
139. Zhou X.D., Agazie Y.M. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ. 2008, 15:988-996.
140. Ke Y., Lesperance J., Zhang E.E., Bard-Chapeau E.A., Oshima R.G., Muller W.J., Feng G.S. Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J. Biol. Chem. 2006, 281:34374-34380.
141. Aceto N., Bentires-Alj M. Targeting protein-tyrosine phosphatases in breast cancer. Oncotarget 2012, 3:514-515.
142. Bard-Chapeau E.A., Li S., Ding J., Zhang S.S., Zhu H.H., Princen F., Fang D.D., Han T., Bailly-Maitre B., Poli V., Varki N.M., Wang H., Feng G.S. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011, 19:629-639.
143. Li S., Hsu D.D., Wang H., Feng G.S. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front. Med. 2012, 6:275-279.
144. Su F., Ren F., Rong Y., Wang Y., Geng Y., Feng M., Ju Y., Li Y., Zhao Z.J., Meng K., Chang Z. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 2012, 14:R38.
145. Sun T., Aceto N., Meerbrey K.L., Kessler J.D., Zhou C., Migliaccio I., Nguyen D.X., Pavlova N.N., Botero M., Huang J., Bernardi R.J., Schmitt E., Hu G., Li M.Z., Dephoure N., Gygi S.P., Rao M., Creighton C.J., Hilsenbeck S.G., Shaw C.A., Muzny D., Gibbs R.A., Wheeler D.A., Osborne C.K., Schiff R., Bentires-Alj M., Elledge S.J., Westbrook T.F. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718.
146. Yuan T., Wang Y., Zhao Z.J., Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J. Biol. Chem. 2010, 285:14861-14870.
147. Huynh H., Bottini N., Williams S., Cherepanov V., Musumeci L., Saito K., Bruckner S., Vachon E., Wang X., Kruger J., Chow C.W., Pellecchia M., Monosov E., Greer P.A., Trimble W., Downey G.P., Mustelin T. Control of vesicle fusion by a tyrosine phosphatase. Nat. Cell Biol. 2004, 6:831-839.
148. Souza C.M., Davidson D., Rhee I., Gratton J.P., Davis E.C., Veillette A. The phosphatase PTP-PEST/PTPN12 regulates endothelial cell migration and adhesion, but not permeability, and controls vascular development and embryonic viability. J. Biol. Chem. 2012, 287:43180-43190.
149. Mathew S., George S.P., Wang Y., Siddiqui M.R., Srinivasan K., Tan L., Khurana S. Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J. Biol. Chem. 2008, 283:22709-22722.
150. Chellaiah M.A., Schaller M.D. Activation of Src kinase by protein-tyrosine phosphatase-PEST in osteoclasts: comparative analysis of the effects of bisphosphonate and protein-tyrosine phosphatase inhibitor on Src activation in vitro. J. Cell. Physiol. 2009, 220:382-393.
151. Villa-Moruzzi E. Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal. Cell. Pathol. (Amst.) 2011, 34:101-112.
152. Streit S., Ruhe J.E., Knyazev P., Knyazeva T., Iacobelli S., Peter S., Hoefler H., Ullrich A. PTP-PEST phosphatase variations in human cancer. Cancer Genet. Cytogenet. 2006, 170:48-53.
153. Harris I.S., Blaser H., Moreno J., Treloar A.E., Gorrini C., Sasaki M., Mason J.M., Knobbe C.B., Rufini A., Halle M., Elia A.J., Wakeham A., Tremblay M.L., Melino G., Done S., Mak T.W. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene 2013, [in press].
154. Gensler M., Buschbeck M., Ullrich A. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. J. Biol. Chem. 2004, 279:12110-12116.
155. Wang B., Lemay S., Tsai S., Veillette A. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF. Mol. Cell. Biol. 2001, 21:1077-1088.
156. Erdmann K.S. The protein tyrosine phosphatase PTP-Basophil/Basophil-like. Interacting proteins and molecular functions. Eur. J. Biochem. 2003, 270:4789-4798.
157. Abaan O.D., Toretsky J.A. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 2008, 27:205-214.
158. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 2005, 331:1-14.
159. Palmer A., Zimmer M., Erdmann K.S., Eulenburg V., Porthin A., Heumann R., Deutsch U., Klein R. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell 2002, 9:725-737.
160. Glondu-Lassis M., Dromard M., Lacroix-Triki M., Nirde P., Puech C., Knani D., Chalbos D., Freiss G. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res. 2010, 70:5116-5126.
161. Zhu J.H., Chen R., Yi W., Cantin G.T., Fearns C., Yang Y., Yates J.R., Lee J.D. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene 2008, 27:2525-2531.
162. Vermeer P.D., Bell M., Lee K., Vermeer D.W., Wieking B.G., Bilal E., Bhanot G., Drapkin R.I., Ganesan S., Klingelhutz A.J., Hendriks W.J., Lee J.H. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. PLoS One 2012, 7:e30447.
163. Revillion F., Puech C., Rabenoelina F., Chalbos D., Peyrat J.P., Freiss G. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int. J. Cancer 2009, 124:638-643.
164. Freiss G., Puech C., Vignon F. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Mol. Endocrinol. 1998, 12:568-579.
165. Bompard G., Puech C., Prebois C., Vignon F., Freiss G. Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. J. Biol. Chem. 2002, 277:47861-47869.
166. Dromard M., Bompard G., Glondu-Lassis M., Puech C., Chalbos D., Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007, 67:6806-6813.
167. Li Y., Kanki H., Hachiya T., Ohyama T., Irie S., Tang G., Mukai J., Sato T. Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells. Int. J. Cancer 2000, 87:473-479.
168. Freiss G., Chalbos D. PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med Chem. 2011, 11:78-88.
169. Pallen C.J. Protein tyrosine phosphatase alpha (PTPalpha): a Src family kinase activator and mediator of multiple biological effects. Curr. Top. Med. Chem. 2003, 3:821-835.
170. Vacaru A.M., den Hertog J. Serine dephosphorylation of receptor protein tyrosine phosphatase alpha in mitosis induces Src binding and activation. Mol. Cell. Biol. 2010, 30:2850-2861.
171. Zheng X.M., Shalloway D. Two mechanisms activate PTPalpha during mitosis. EMBO J. 2001, 20:6037-6049.
172. Zheng X.M., Resnick R.J., Shalloway D. A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J. 2000, 19:964-978.
173. Kraut-Cohen J., Muller W.J., Elson A. Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling. J. Biol. Chem. 2008, 283:4612-4621.
174. Sun G., Cheng S.Y., Chen M., Lim C.J., Pallen C.J. Protein tyrosine phosphatase alpha phosphotyrosyl-789 binds BCAR3 to position Cas for activation at integrin-mediated focal adhesions. Mol. Cell. Biol. 2012, 32:3776-3789.
175. Berman-Golan D., Elson A. Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells. Oncogene 2007, 26:7028-7037.
176. Nunes-Xavier C.E., Elson A., Pulido R. EGFR-mediated positive feedback of PTPepsilon on ERK1/2 and AKT pathways is required for survival of human breast cancer cells. J. Biol. Chem. 2012, 287:3433-3444.
177. Elson A., Leder P. Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu. J. Biol. Chem. 1995, 270:26116-26122.
178. Elson A. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Oncogene 1999, 18:7535-7542.
179. Gil-Henn H., Elson A. Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells. J. Biol. Chem. 2003, 278:15579-15586.
180. Ardini E., Agresti R., Tagliabue E., Greco M., Aiello P., Yang L.T., Menard S., Sap J. Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene 2000, 19:4979-4987.
181. Huang J., Yao L., Xu R., Wu H., Wang M., White B.S., Shalloway D., Zheng X. Activation of Src and transformation by an RPTPalpha splice mutant found in human tumours. EMBO J. 2011, 30:3200-3211.
182. Zheng X., Resnick R.J., Shalloway D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. Int. J. Cancer 2008, 122:1999-2007.
183. Sanchez-Bailon M.P., Calcabrini A., Gomez-Dominguez D., Morte B., Martin-Forero E., Gomez-Lopez G., Molinari A., Wagner K.U., Martin-Perez J. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell. Signal. 2012, 24:1276-1286.
184. Bjorge J.D., Pang A.S., Funnell M., Chen K.Y., Diaz R., Magliocco A.M., Fujita D.J. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS One 2011, 6:e19309.
185. Ishizawar R.C., Tice D.A., Karaoli T., Parsons S.J. The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J. Biol. Chem. 2004, 279:23773-23781.
186. Finn R.S. Targeting Src in breast cancer. Ann. Oncol. 2008, 19:1379-1386.
187. Mayer E.L., Krop I.E. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer Res. 2010, 16:3526-3532.
188. Ito T., Okazawa H., Maruyama K., Tomizawa K., Motegi S., Ohnishi H., Kuwano H., Kosugi A., Matozaki T. Interaction of SAP-1, a transmembrane-type protein-tyrosine phosphatase, with the tyrosine kinase Lck. Roles in regulation of T cell function. J. Biol. Chem. 2003, 278:34854-34863.
189. Nagano ]H., Noguchi T., Inagaki K., Yoon S., Matozaki T., Itoh H., Kasuga M., Hayashi Y. Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma. Oncogene 2003, 22:4656-4663.
190. Seo Y., Matozaki T., Tsuda M., Hayashi Y., Itoh H., Kasuga M. Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. Biochem. Biophys. Res. Commun. 1997, 231:705-711.
191. Sadakata H., Okazawa H., Sato T., Supriatna Y., Ohnishi H., Kusakari S., Murata Y., Ito T., Nishiyama U., Minegishi T., Harada A., Matozaki T. SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis. Genes Cells 2009, 14:295-308.
192. Lin G., Aranda V., Muthuswamy S.K., Tonks N.K. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev. 2011, 25:1412-1425.
193. Mariotti M., Castiglioni S., Garcia-Manteiga J.M., Beguinot L., Maier J.A. HD-PTP inhibits endothelial migration through its interaction with Src. Int. J. Biochem. Cell Biol. 2009, 41:687-693.
194. Solomon D.A., Kim J.S., Cronin J.C., Sibenaller Z., Ryken T., Rosenberg S.A., Ressom H., Jean W., Bigner D., Yan H., Samuels Y., Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 2008, 68:10300-10306.
195. Veeriah S., Brennan C., Meng S., Singh B., Fagin J.A., Solit D.B., Paty P.B., Rohle D., Vivanco I., Chmielecki J., Pao W., Ladanyi M., Gerald W.L., Liau L., Cloughesy T.C., Mischel P.S., Sander C., Taylor B., Schultz N., Major J., Heguy A., Fang F., Mellinghoff I.K., Chan T.A. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9435-9440.
196. Meehan M., Parthasarathi L., Moran N., Jefferies C.A., Foley N., Lazzari E., Murphy D., Ryan J., Ortiz B., Fabius A.W., Chan T.A., Stallings R.L. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol. Cancer 2012, 11:6.
197. Chan T.A., Glockner S., Yi J.M., Chen W., Van Neste L., Cope L., Herman J.G., Velculescu V., Schuebel K.E., Ahuja N., Baylin S.B. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008, 5:e114.
198. Panagopoulos I., Pandis N., Thelin S., Petersson C., Mertens F., Borg A., Kristoffersson U., Mitelman F., Aman P. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 1996, 56:4871-4875.
199. Zheng J., Kulp S.K., Zhang Y., Sugimoto Y., Dayton M.A., Govindan M.V., Brueggemeier R.W., Lin Y.C. 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. Anticancer Res. 2000, 20:11-19.
200. Liu S., Sugimoto Y., Kulp S.K., Jiang J., Chang H.L., Park K.Y., Kashida Y., Lin Y.C. Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Res. 2002, 22:3917-3923.
201. Shu S.T., Sugimoto Y., Liu S., Chang H.L., Ye W., Wang L.S., Huang Y.W., Yan P., Lin Y.C. Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res. 2010, 30:1937-1946.
202. van Roon E.H., de Miranda N.F., van Nieuwenhuizen M.P., de Meijer E.J., van Puijenbroek M., Yan P.S., Huang T.H., van Wezel T., Morreau H., Boer J.M. Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. Eur. J. Hum. Genet. 2011, 19:307-312.
203. Liu S., Sugimoto Y., Sorio C., Tecchio C., Lin Y.C. Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. Oncogene 2004, 23:1256-1262.
204. Wang L.S., Huang Y.W., Sugimoto Y., Liu S., Chang H.L., Ye W., Shu S., Lin Y.C. Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells. Anticancer Res. 2006, 26:27-34.
205. Druck T., Kastury K., Hadaczek P., Podolski J., Toloczko A., Sikorski A., Ohta M., LaForgia S., Lasota J., McCue P., et al. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res. 1995, 55:5348-5353.
206. Boucher C.A., Ward H.H., Case R.L., Thurston K.S., Li X., Needham A., Romero E., Hyink D., Qamar S., Roitbak T., Powell S., Ward C., Wilson P.D., Wandinger-Ness A., Sandford R.N. Receptor protein tyrosine phosphatases are novel components of a polycystin complex. Biochim. Biophys. Acta 2011, 1812:1225-1238.
207. Scott A., Wang Z. Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci. Rep. 2011, 31:303-307.
208. Aricescu A.R., Siebold C., Jones E.Y. Receptor protein tyrosine phosphatase micro: measuring where to stick. Biochem. Soc. Trans. 2008, 36:167-172.
209. Zondag G.C., Reynolds A.B., Moolenaar W.H. Receptor protein-tyrosine phosphatase RPTPmu binds to and dephosphorylates the catenin p120(ctn). J. Biol. Chem. 2000, 275:11264-11269.
210. Phillips-Mason P.J., Kaur H., Burden-Gulley S.M., Craig S.E., Brady-Kalnay S.M. Identification of phospholipase C gamma1 as a protein tyrosine phosphatase mu substrate that regulates cell migration. J. Cell. Biochem. 2011, 112:39-48.
211. Sun P.H., Ye L., Mason M.D., Jiang W.G. Protein tyrosine phosphatase micro (PTP micro or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis. PLoS One 2012, 7:e50183.
212. Burgoyne A.M., Phillips-Mason P.J., Burden-Gulley S.M., Robinson S., Sloan A.E., Miller R.H., Brady-Kalnay S.M. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res. 2009, 69:6960-6968.
213. Tozlu S., Girault I., Vacher S., Vendrell J., Andrieu C., Spyratos F., Cohen P., Lidereau R., Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 2006, 13:1109-1120.
214. Lee J.W., Jeong E.G., Lee S.H., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J. Mutational analysis of PTPRT phosphatase domains in common human cancers. APMIS 2007, 115:47-51.
215. Lim S.H., Kwon S.K., Lee M.K., Moon J., Jeong D.G., Park E., Kim S.J., Park B.C., Lee S.C., Ryu S.E., Yu D.Y., Chung B.H., Kim E., Myung P.K., Lee J.R. Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J. 2009, 28:3564-3578.
216. Zhang X., Guo A., Yu J., Possemato A., Chen Y., Zheng W., Polakiewicz R.D., Kinzler K.W., Vogelstein B., Velculescu V.E., Wang Z.J. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4060-4064.
217. Zhao Y., Zhang X., Guda K., Lawrence E., Sun Q., Watanabe T., Iwakura Y., Asano M., Wei L., Yang Z., Zheng W., Dawson D., Willis J., Markowitz S.D., Satake M., Wang Z. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2592-2597.
218. Jing M., Bohl J., Brimer N., Kinter M., Vande Pol S.B. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J. Virol. 2007, 81:2231-2239.
219. Spanos W.C., Hoover A., Harris G.F., Wu S., Strand G.L., Anderson M.E., Klingelhutz A.J., Hendriks W., Bossler A.D., Lee J.H. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 2008, 82:2493-2500.
220. Jung Y., Kim P., Keum J., Kim S.N., Choi Y.S., Do I.G., Lee J., Choi S.J., Kim S., Lee J.E., Kim J., Lee S. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012, 51:590-597.
221. Han S., Williams S., Mustelin T. Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling. Eur. J. Immunol. 2000, 30:1318-1325.
222. Sozio M.S., Mathis M.A., Young J.A., Walchli S., Pitcher L.A., Wrage P.C., Bartok B., Campbell A., Watts J.D., Aebersold R., Hooft van Huijsduijnen R., van Oers N.S. PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit. J. Biol. Chem. 2004, 279:7760-7769.
223. Hou S.W., Zhi H.Y., Pohl N., Loesch M., Qi X.M., Li R.S., Basir Z., Chen G. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. Cancer Res. 2010, 70:2901-2910.
224. Zhi H.Y., Hou S.W., Li R.S., Basir Z., Xiang Q., Szabo A., Chen G. PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization. Oncogene 2011, 30:1706-1715.
225. Pilecka I., Patrignani C., Pescini R., Curchod M.L., Perrin D., Xue Y., Yasenchak J., Clark A., Magnone M.C., Zaratin P., Valenzuela D., Rommel C., Hooft van Huijsduijnen R. Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J. Biol. Chem. 2007, 282:35405-35415.
226. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
227. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 2009, 15:7479-7491.
228. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci. 2011, 102:1-8.
229. Murphy C.G., Morris P.G. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012, 23:765-776.
230. O'Regan R., Hawk N.N. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin. Ther. Targets 2011, 15:859-872.
231. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
232. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
233. Barone I., Giordano C., Malivindi R., Lanzino M., Rizza P., Casaburi I., Bonofiglio D., Catalano S., Ando S. Estrogens and PTP1B function in a novel pathway to regulate aromatase enzymatic activity in breast cancer cells. Endocrinology 2012, 153:5157-5166.
234. Chang H.L., Sugimoto Y., Liu S., Ye W., Wang L.S., Huang Y.W., Lin Y.C. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res. 2006, 26:1773-1784.
235. Hopp T.A., Weiss H.L., Parra I.S., Cui Y., Osborne C.K., Fuqua S.A. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin. Cancer Res. 2004, 10:7490-7499.
236. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., Sahin A.A., Esteva F.J., Hortobagyi G.N., Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
237. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem. 2009, 16:706-733.
238. Barr A.J. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med. Chem. 2010, 2:1563-1576.
239. Scott L.M., Lawrence H.R., Sebti S.M., Lawrence N.J., Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des. 2010, 16:1843-1862.
240. Patel D., Jain M., Shah S.R., Bahekar R., Jadav P., Darji B., Siriki Y., Bandyopadhyay D., Joharapurkar A., Kshirsagar S., Patel H., Shaikh M., Sairam K.V., Patel P. Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors. ChemMedChem 2011, 6:1011-1016.
241. Patel D., Jain M., Shah S.R., Bahekar R., Jadav P., Joharapurkar A., Dhanesha N., Shaikh M., Sairam K.V., Kapadnis P. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:1111-1117.
242. Ottana R., Maccari R., Amuso S., Wolber G., Schuster D., Herdlinger S., Manao G., Camici G., Paoli P. New 4-[(5-arylidene-2-arylimino-4-oxo-3-thiazolidinyl)methyl]benzoic acids active as protein tyrosine phosphatase inhibitors endowed with insulinomimetic effect on mouse C2C12 skeletal muscle cells. Eur. J. Med. Chem. 2012, 50:332-343.
243. Mullauer F.B., Kessler J.H., Medema J.P. Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010, 21:215-227.
244. Mertens-Talcott S.U., Noratto G.D., Li X., Angel-Morales G., Bertoldi M.C., Safe S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10. Mol. Carcinog. 2012, [in press].
245. Koizumi M., Takagi-Sato M., Okuyama R., Araki K., Sun W., Nakai D. In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides. Nucleic Acids Symp. Ser. (Oxf.) 2007, 111-112.
246. Yang Y.M., Seo S.Y., Kim T.H., Kim S.G. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid. Hepatology 2012, 56:2209-2220.
247. Haque A., Andersen J.N., Salmeen A., Barford D., Tonks N.K. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 2011, 147:185-198.
248. Chen L., Pernazza D., Scott L.M., Lawrence H.R., Ren Y., Luo Y., Wu X., Sung S.S., Guida W.C., Sebti S.M., Lawrence N.J., Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem. Pharmacol. 2010, 80:801-810.
249. Zhang X., He Y., Liu S., Yu Z., Jiang Z.X., Yang Z., Dong Y., Nabinger S.C., Wu L., Gunawan A.M., Wang L., Chan R.J., Zhang Z.Y. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 2010, 53:2482-2493.
250. Liu D., Kong G., Chen Q.C., Wang G., Li J., Xu Y., Lin T., Tian Y., Zhang X., Yao X., Feng G., Lu Z., Chen H. Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. Bioorg. Med. Chem. Lett. 2011, 21:6833-6837.
251. Kundu S., Fan K., Cao M., Lindner D.J., Zhao Z.J., Borden E., Yi T. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J. Immunol. 2010, 184:6529-6536.
252. Yi T., Elson P., Mitsuhashi M., Jacobs B., Hollovary E., Budd T.G., Spiro T., Triozzi P., Borden E.C. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget 2011, 2:1155-1164.
253. Naing A., Reuben J.M., Camacho L.H., Gao H., Lee B.N., Cohen E.N., Verschraegen C., Stephen S., Aaron J., Hong D., Wheler J., Kurzrock R. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor. Combined with interferon alpha for patients with solid tumors. J. Cancer 2011, 2:81-89.
254. Winter M.C., Coleman R.E. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr. Opin. Oncol. 2009, 21:499-506.
255. Holen I., Coleman R.E. Bisphosphonates as treatment of bone metastases. Curr. Pharm. Des. 2010, 16:1262-1271.
256. Granot-Attas S., Elson A. Protein tyrosine phosphatases in osteoclast differentiation, adhesion, and bone resorption. Eur. J. Cell Biol. 2008, 87:479-490.
257. Schmidt A., Rutledge S.J., Endo N., Opas E.E., Tanaka H., Wesolowski G., Leu C.T., Huang Z., Ramachandaran C., Rodan S.B., Rodan G.A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3068-3073.
258. Skorey K., Ly H.D., Kelly J., Hammond M., Ramachandran C., Huang Z., Gresser M.J., Wang Q. How does alendronate inhibit protein-tyrosine phosphatases?. J. Biol. Chem. 1997, 272:22472-22480.
259. Holen I., Coleman R.E. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010, 12:214.
260. McCain D.F., Wu L., Nickel P., Kassack M.U., Kreimeyer A., Gagliardi A., Collins D.C., Zhang Z.Y. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases. J. Biol. Chem. 2004, 279:14713-14725.
261. Takahashi K., Mernaugh R.L., Friedman D.B., Weller R., Tsuboi N., Yamashita H., Quaranta V., Takahashi T. Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1985-1990.
262. Earl L.A., Bi S., Baum L.G. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J. Biol. Chem. 2010, 285:2232-2244.
263. Perez-Pinera P., Zhang W., Chang Y., Vega J.A., Deuel T.F. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J. Biol. Chem. 2007, 282:28683-28690.
264. Duces A., Karaky R., Martel-Renoir D., Mir L., Hamma-Kourbali Y., Bieche I., Opolon P., Delbe J., Courty J., Perricaudet M., Griscelli F. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. Mol. Cancer Ther. 2008, 7:2817-2827.
265. Mikelis C., Lamprou M., Koutsioumpa M., Koutsioubas A.G., Spyranti Z., Zompra A.A., Spiliopoulos N., Vradis A.A., Katsoris P., Spyroulias G.A., Cordopatis P., Courty J., Papadimitriou E. A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro. J. Cell. Biochem. 2011, 112:1532-1543.
266. Kalemi T.G., Papazisis K.T., Lambropoulos A.F., Voyatzi S., Kotsis A., Kortsaris A.H. Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1). Anticancer Res. 2007, 27:913-920.
267. Elsberger B., Fullerton R., Zino S., Jordan F., Mitchell T.J., Brunton V.G., Mallon E.A., Shiels P.G., Edwards J. Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br. J. Cancer 2010, 103:899-909.
268. Vogel W., Ullrich A. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ. 1996, 7:1589-1597.
269. Frank C., Burkhardt C., Imhof D., Ringel J., Zschornig O., Wieligmann K., Zacharias M., Bohmer F.D. Effective dephosphorylation of Src substrates by SHP-1. J. Biol. Chem. 2004, 279:11375-11383.
270. Liu F., Chernoff J. Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Biochem. J. 1997, 327(Pt 1):139-145.
271. Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F., Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr. Biol. 2009, 19:1788-1798.
272. Thangaraju M., Sharma K., Leber B., Andrews D.W., Shen S.H., Srikant C.B. Regulation of acidification and apoptosis by SHP-1 and Bcl-2. J. Biol. Chem. 1999, 274:29549-29557.
273. Xunyi Y., Zhentao Y., Dandan J., Funian L. Clinicopathological significance of PTPN12 expression in human breast cancer. Braz. J. Med. Biol. Res. 2012, 45:1334-1340.
274. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Nasser V., Loriod B., Camerlo J., Tagett R., Tarpin C., Houvenaeghel G., Nguyen C., Maraninchi D., Jacquemier J., Houlgatte R., Birnbaum D., Viens P. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 2004, 64:8558-8565.